MedTrace Logo

Treat-and-extend Using Aflibercept for Type 3 Neovascularization

NCT04655482 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-08-22

No results posted yet for this study

Summary

Type 3 neovascularization is a subtype of neovascular age-related macular degeneration (AMD) that is characterized by intraretinal neovascularization. Treat-and-extend (TAE) regimen is a widely-used, effective anti-vascular endothelial growth factor treatment regimen for neovascular AMD, regardless of subtypes of AMD. The purpose of the present study is to investigate the 18-month treatment outcome of TAE in type 3 neovascularization.

Conditions

  • Retinal Angiomatous Proliferation

Interventions

DRUG

Aflibercept Injection

Intravitreal injection of aflibercept using treat-and-extend regimen :Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Kim's Eye Hospital

    lead OTHER

Principal Investigators

  • Jae Hui Kim, M.D. · Kim's Eye Hospital, Seoul, South Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-12-20
Completion
2024-08-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04655482 on ClinicalTrials.gov